The DOI matches its Crossref record; 52 of the 55 references it cites were found in a registry or an index.
Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss
Open accessAbstract
A molecular basis for memory failure in Alzheimer's disease (AD) has been recently hypothesized, in which a significant role is attributed to small, soluble oligomers of amyloid beta-peptide (A beta). A beta oligomeric ligands (also known as ADDLs) are known to be potent inhibitors of hippocampal long-term potentiation, which is a paradigm for synaptic plasticity, and have been linked to synapse loss and reversible memory failure in transgenic mouse AD models. If such oligomers were to build up in human brain, their neurological impact could provide the missing link that accounts for the poor correlation between AD dementia and amyloid plaques. This article, using antibodies raised against synthetic A beta oligomers, verifies the predicted accumulation of soluble oligomers in AD frontal cortex. Oligomers in AD reach levels up to 70-fold over control brains. Brain-derived and synthetic oligomers show structural equivalence with respect to mass, isoelectric point, and recognition by conformation-sensitive antibodies. Both oligomers, moreover, exhibit the same striking patterns of attachment to cultured hippocampal neurons, binding on dendrite surfaces in small clusters with ligand-like specificity. Binding assays using solubilized membranes show oligomers to be high-affinity ligands for a small number of nonabundant proteins. Current results confirm the prediction that soluble oligomeric A beta ligands are intrinsic to AD pathology, and validate their use in new approaches to therapeutic AD drugs and vaccines.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, recent in vivo studies have shown that soluble Aβ oligomers are more neurotoxic than amyloid plaques and most likely responsible for synaptic dysfunction and memory loss in AD.7–11”
From The effect of Cu2+ and Zn2+ on the Aβ42 peptide aggregation and cellular toxicity (2013) · cites this paper as [11]
In the citing paper
“However, recent in vivo studies have shown that the soluble Aβ oligomers are possibly more neurotoxic than amyloid plaques,14–17 and are likely responsible for synaptic dysfunction and memory loss in AD patients and AD animal models.18–21”
From Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide (2012) · cites this paper as [18]
In the citing paper
“which was also shown to form neurotoxic soluble Aβ oligomers.18–20”
From Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide (2012) · cites this paper as [18]
In the citing paper
“recent studies have shown that the soluble Aβ oligomers are more neurotoxic both in vitro and in vivo.5−8”
From Small Bifunctional Chelators That Do Not Disaggregate Amyloid β Fibrils Exhibit Reduced Cellular Toxicity (2014) · cites this paper as [8]
In the citing paper
“the Aβ42 peptide was employed in these studies because it was shown to form neurotoxic soluble Aβ oligomers.5,8,48”
From Small Bifunctional Chelators That Do Not Disaggregate Amyloid β Fibrils Exhibit Reduced Cellular Toxicity (2014) · cites this paper as [8]
In the citing paper
“Dot immunoblots of soluble extracts from human brain show major increases in oligomers in AD-affected tissue (Gong et al., 2003; Kayed et al., 2003; Lambert et al., 2001).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Gong et al., 2003
In the citing paper
“as have the related predictions that oligomers cause dysfunctional trafficking of ionotropic glutamate receptors and metabotropic glutamate receptors (Gong et al., 2003; Lacor et al., 2004).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Gong et al., 2003
In the citing paper
“Cultured hippocampal neurons incubated with brain-derived oligomers show patterns that recapitulate the in situ distribution (Gong et al., 2003).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Gong et al., 2003
In the citing paper
“Because Arc is an actin binding protein, its aberrant expression was predicted to disrupt receptor trafficking (Lacor et al., 2004), which could consequently disrupt plasticity (Gong et al., 2003).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Gong et al., 2003
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Lipid rafts and signal transduction
Simons, K., & Toomre, D. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35036052 · Cited by 5,371
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Self-citation
Research works printed but not linked: 2
- Terry R. D. (1999) in Alzheimer Disease eds. Terry R. D. Katzman R. Bick K. L. & Sisodia S. S. (Lippincott Williams & Wilkins Philadelphia) pp. 187-206.
- Chang L. Gong Y. Bakhos L. Yu J. Venton D. L. & Klein W. L. (2003) J. Mol. Neurosci. in press.
Cited by
Sorted by citations
Items 601–700 of 1,000
Protein-Protein Interactions and Aggregation Inhibitors in Alzheimer’s Disease
Ganeshpurkar, A., Swetha, R., Kumar, D., Gangaram, G. P., Singh, R., Gutti, G., Jana, S., Kumar, D., Kumar, A., & Singh, S. K. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190304153353 · Cited by 30
Andersson, E., Lindblom, N., Janelidze, S., Salvadó, G., Gkanatsiou, E., Söderberg, L., Möller, C., Lannfelt, L., Ge, J., Hanrieder, J., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00810-8 · Cited by 38
de Almeida, N. E. C., Do, T. D., LaPointe, N. E., Jhatro, M., Feinstein, S. C., Shea, J., & Bowers, M. T. (2016) · International Journal of Mass Spectrometry · doi:10.1016/j.ijms.2016.09.018 · Cited by 30
Experimental evidence of tyrosine neurotoxicity: focus on mitochondrial dysfunction
de Oliveira, J., Farias, H. R., & STRECK, E. L. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00781-w · Cited by 30
α-synuclein-assisted oligomerization of β-amyloid (1–42)
Chau, E., & Kim, J. R. (2022) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2022.109120 · Cited by 30
Disassembly of preformed amyloid beta fibrils by small organofluorine molecules
Sood, A., Abid, M. A., Sauer, C., Hailemichael, S., Foster, M. C., Török, B., & Török, M. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.02.012 · Cited by 32
Dopamine release in prefrontal cortex in response to β-amyloid activation of α7∗ nicotinic receptors
Wu, J., Khan, G. M., & Nichols, R. A. (2007) · Brain Research · doi:10.1016/j.brainres.2007.08.079 · Cited by 30
Barucker, C., Bittner, H. J., Chang, P. K. ‐., Cameron, S., Hancock, M. A., Liebsch, F., Hossain, S., Harmeier, A., Shaw, H. S., Charron, F. M., et al. (2015) · Scientific Reports · doi:10.1038/srep15410 · Cited by 32
Warner, C. J. A., Dutta, S., Foley, A. R., & Raskatov, J. A. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201601763 · Cited by 30
Drebrin in Alzheimer’s Disease
Ishizuka, Y., & Hanamura, K. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-4-431-56550-5_12 · Cited by 32
Wang, J. S.-H., Whitehead, S. N., & Yeung, K. K. ‐. (2018) · Journal of the American Society for Mass Spectrometry · doi:10.1007/s13361-018-1896-z · Cited by 31
Lambert, M., Velasco, P., Viola, K., & Klein, W. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787601876 · Cited by 29
Self-citationAmyloid‐β Aggregation with Gold Nanoparticles on Brain Lipid Bilayer
Lee, H., Kim, Y., Park, A., & Nam, J. (2014) · Small · doi:10.1002/smll.201303242 · Cited by 29
Brain Aging and Late-Onset Alzheimer’s Disease: A Matter of Increased Amyloid or Reduced Energy?
Mecocci, P., Baroni, M., Senin, U., & Boccardi, V. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179903 · Cited by 30
Trapping and Characterization of Nontoxic Aβ42 Aggregation Intermediates
Foley, A. R., Finn, T. S., Kung, T., Hatami, A., Lee, H., Jia, M., Rolandi, M., & Raskatov, J. A. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00340 · Cited by 29
Modification of Aβ Peptide Aggregation via Covalent Binding of a Series of Ru(III) Complexes
Gomes, L. M., Bataglioli, J. C., Jussila, A. J., Smith, J. R., Walsby, C. J., & Storr, T. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00838 · Cited by 29
Bataglioli, J. C., Gomes, L. M., Maunoir, C., Smith, J. R., Cole, H. D., McCain, J., Sainuddin, T., Cameron, C. G., McFarland, S. A., & Storr, T. (2021) · Chemical Science · doi:10.1039/d1sc00004g · Cited by 29
Cyclooxygenase-Dependent Lipid-Modification of Brain Proteins
Boutaud, O. G., Andreasson, K. I., Zagol-Ikapitte, I. A., & Oates, J. A. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2005.tb00510.x · Cited by 29
Consideration of the ischaemic basis and treatment of Alzheimer's disease.
Pluta, R. M., Ułamek, M., & Jabłoński, M. (2010) · PubMed · Cited by 29
A presenilin‐independent aspartyl protease prefers the γ‐42 site cleavage
Lai, M., Crouthamel, M., DiMuzio, J. M., Pietrak, B., Donoviel, D. B., Bernstein, A., Gardell, S. J., Li, Y., & Hazuda, D. J. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03528.x · Cited by 31
Protein phosphatase 5 protects neurons against amyloid‐β toxicity
Sanchez‐Ortiz, E., Hahm, B. K., Armstrong, D. L., & Rossie, S. S. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06337.x · Cited by 29
Parsons, C. G., & Rammes, G. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1313832 · Cited by 29
Viola, K. L., Bicca, M. A., Bebenek, A. M., Kranz, D. L., Nandwana, V., Waters, E. A., Haney, C. R., Lee, M. Y., Gupta, A., Brahmbhatt, Z., et al. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.768646 · Cited by 29
Self-citationMontanari, S., Bartolini, M., Neviani, P., Belluti, F., Gobbi, S., Pruccoli, L., Tarozzi, A., Falchi, F., Andrisano, V., Miszta, P., et al. (2015) · ChemMedChem · doi:10.1002/cmdc.201500392 · Cited by 28
Mouse Models of Alzheimer’s Dementia: Current Concepts and New Trends
Torres‐Alemán, I. (2008) · Endocrinology · doi:10.1210/en.2008-0905 · Cited by 28
Zhou, S.-F., Zhang, L., Zhou, Z.-W., Wang, Z., Du, Y.-H., He, Z., & Cao, C. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s71106 · Cited by 28
RetractedPellistri, F., Bucciantini, M., Invernizzi, G., Gatta, E., Penco, A., Frana, A. M., Nosi, D., Relini, A., Regonesi, M. E., Gliozzi, A., et al. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.08.019 · Cited by 29
Xiao, Y., Matsuda, I., Inoue, M., Sasahara, T., Hoshi, M. M., & Ishii, Y. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.008522 · Cited by 28
Targeting Pathological Amyloid Aggregates with Conformation-Sensitive Antibodies
Bigi, A., Loffredo, G., Cascella, R., & Cecchi, C. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666201109093848 · Cited by 29
Vaisid, T., Kosower, N. S., Elkind, E., & Barnoy, S. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21670 · Cited by 27
Cellamare, S., Stefanachi, A., Stolfa, D. A., Basile, T., Catto, M., Campagna, F., Sotelo, E., Acquafredda, P., & Carotti, A. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.03.052 · Cited by 27
Alzheimer's Disease:Progress in the Development of Anti-amyloid Disease-Modifying Therapies
Christensen, D. D. (2007) · CNS Spectrums · doi:10.1017/s1092852900020629 · Cited by 27
Caraci, F., Pappalardo, G., Basile, L., Giuffrida, A., Copani, A., Tosto, R., Sinopoli, A., Giuffrida, M. L., Pirrone, E., Drago, F., et al. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.07.015 · Cited by 23
Liu, M.-L., & Hong, S. (2005) · Experimental & Molecular Medicine · doi:10.1038/emm.2005.69 · Cited by 29
Murti, B. T., Putri, A. D., Huang, Y., Wei, S.-M., Peng, C., & Yang, P. (2021) · RSC Advances · doi:10.1039/d1ra01553b · Cited by 28
Han, F., Zhuang, T.-T., Chen, J., Zhu, X.-L., Cai, Y., & Lu, Y.-P. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185102 · Cited by 26
Tsuda, M., Kobayashi, T., Matsuo, T., & Aigaki, T. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.05.010 · Cited by 26
Sandberg, A., Berenjeno‐Correa, E., Rodriguez, R. C., Axenhus, M., Weiss, S. S., Batenburg, K. L., Hoozemans, J. J. M., Tjernberg, L. O., & Scheper, W. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01141-1 · Cited by 29
The Role of Oxytocin in Alzheimer’s Disease and Its Relationship with Social Interaction
Takahashi, J., Yamada, D., Nagano, W., & Saitoh, A. (2023) · Cells · doi:10.3390/cells12202426 · Cited by 25
Elucidating Molecular Mass and Shape of a Neurotoxic Aβ Oligomer
Sebollela, A. S., Mustata, G.-M., Luo, K., Velasco, P. T., Viola, K. L., Cline, E. N., Shekhawat, G. S., Wilcox, K. C., Dravid, V. P., & Klein, W. L. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500156r · Cited by 25
Self-citationDiChiara, T., DiNunno, N., Clark, J. R., Bu, R. L., Cline, E. N., Rollins, M. G., Gong, Y., Brody, D. L., Sligar, S. G., Velasco, P. T., et al. (2017) · PubMed · Cited by 25
Self-citationCline, E. N., Das, A., Bicca, M. A., Mohammad, S. N., Schachner, L. F., Kamel, J. M., DiNunno, N., Weng, A., Paschall, J. D., Bu, R. L., et al. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14647 · Cited by 25
Self-citationDatki, Z., Galik-Olah, Z., Mózes, E., Szegedi, V., Kálmán, J., Hunya, Á. G., Fülöp, L., Tamano, H., Takeda, A., Adlard, P. A., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0800-y · Cited by 25
Muscone Ameliorates Synaptic Dysfunction and Cognitive Deficits in APP/PS1 Mice
Liu, Y., Bian, H., Xu, S., Shu, S., Jia, J., Chen, J., Cao, X., Bao, X., Gu, Y., Xia, S., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200188 · Cited by 26
CSF-studies in neuropsychiatric disorders.
Raedler, T. J., & Wiedemann, K. (2006) · PubMed · Cited by 25
Early diagnostics and therapeutics for Alzheimer’s disease – how early can we get there?
Monien, B. H., Apostolova, L. G., & Bitan, G. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.9.1293 · Cited by 27
The immunotherapy of Alzheimer's disease
Weksler, M. E. (2004) · Immunity & Ageing · doi:10.1186/1742-4933-1-2 · Cited by 25
Stefani, M. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-756-3_2 · Cited by 25
Jang, Y., Jang, H., Kim, G. H., Noh, J., Chang, K., & Lee, K. J. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12686 · Cited by 24
Neuroimmunomodulation by calcineurin in aging and Alzheimer's disease.
Reese, L. C., & Taglialatela, G. (2010) · Europe PMC (PubMed Central) · Cited by 26
Brain amyloid β protein and memory disruption in Alzheimer’s disease
Xia, W. (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s7460 · Cited by 24
Molecular Determinants of Aβ 42 Adsorption to Amyloid Fibril Surfaces
Bellaiche, M. M. J., & Best, R. B. (2018) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.8b02375 · Cited by 24
Malik, B. A., Fernandes, C., Killick, R., Wroe, R., Usardi, A., Williamson, R., Kellie, S., Anderton, B. H., & Reynolds, C. H. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.05.006 · Cited by 27
Frackowiak, J., Potempska, A., & Mazur‐Kolecka, B. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0497-0 · Cited by 24
Lahiri, D. K., & Greig, N. H. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.02.002 · Cited by 26
Wang, Y., Zheng, A., Yang, H., Wang, Q., Ren, B. X., Guo, T., Qiang, J., Cao, H., Gao, Y., Xu, L., et al. (2021) · Journal of Integrative Neuroscience · doi:10.31083/j.jin.2021.01.224 · Cited by 23
Long, F., Cho, W., & Ishii, Y. (2011) · Protein Expression and Purification · doi:10.1016/j.pep.2011.05.012 · Cited by 23
Glia: dos velhos conceitos às novas funções de hoje e as que ainda virão
Gomes, F. C. A., Tortelli, V., & Diniz, L. P. (2013) · Estudos Avançados · doi:10.1590/s0103-40142013000100006 · Cited by 29
Delacourte, A., Campion, D., & Davous, P. (2007) · Encyclopédie médico-chirurgicale. Neurologie · doi:10.1016/s0246-0378(07)44093-3 · Cited by 23
Rudinskiy, N., Fuerer, C., Demurtas, D., Zamorano, S., Piano, C. D., Herrmann, A. G., Spires‐Jones, T. L., Oeckl, P., Otto, M., Frosch, M. P., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.03.011 · Cited by 25
Bate, C., & Williams, A. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100528 · Cited by 23
Omi is a mammalian heat-shock protein that selectively binds and detoxifies oligomeric amyloid-β
Liu, M.-L., Liu, M.-J., Shen, Y.-F., Ryu, H., Kim, H., Klupsch, K., Downward, J., & Hong, S. (2009) · Journal of Cell Science · doi:10.1242/jcs.042226 · Cited by 23
Klein, W. L., Lacor, P. N., Felice, F. G. D., & Ferreira, S. T. (2007) · Research and perspectives in neurosciences · doi:10.1007/978-3-540-45702-2_11 · Cited by 23
Self-citationA single-domain antibody detects and neutralises toxic Aβ42 oligomers in the Alzheimer’s disease CSF
Bigi, A., Napolitano, L., Vadukul, D. M., Chiti, F., Cecchi, C., Aprile, F. A., & Cascella, R. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01361-z · Cited by 23
Kumar, S., Okello, E. J., & Harris, J. R. (2012) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-5416-4_13 · Cited by 23
Mališauskas, M., Darinskas, A., Zamotin, V., Gharibyan, A. L., Kostanyan, I. A., & Morozova‐Roche, L. A. (2006) · Biochemistry (Moscow) · doi:10.1134/s0006297906050063 · Cited by 22
Characterization of the Brain β-Amyloid Isoform Pattern at Different Ages of Tg2576 Mice
Mustafiz, T., Portelius, E., Gustavsson, M. K., Hölttä, M., Zetterberg, H., Blennow, K., Nordberg, A. K., & Lithner, C. U. (2011) · Neurodegenerative Diseases · doi:10.1159/000323871 · Cited by 22
Bate, C., & Williams, A. (2015) · Biology · doi:10.3390/biology4030591 · Cited by 22
Yu, L., Wu, A., Wong, V. K. W., Qu, L., Zhang, N., Qin, D., Wu, J., Tang, B., Wang, H.-M., Wang, Q., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00194 · Cited by 22
Advanced analytical methodologies in Alzheimer’s disease drug discovery
Simone, A. D., Naldi, M., Tedesco, D., Bartolini, M., Davani, L., & Andrisano, V. (2019) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2019.112899 · Cited by 22
Wasilewski, D., Villalba‐Moreno, N. D., Stange, I., Glatzel, M., Falla, D. S., & Krasemann, S. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.739411 · Cited by 23
Yang, W. J., Woltjer, R. L., Sokal, I., Pan, C., Wang, Y., Brodey, M., Peskind, E. R., Leverenz, J. B., Zhang, J., Perl, D. P., et al. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070015 · Cited by 22
Fessel, J. (2017) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4730 · Cited by 24
En route to early diagnosis of Alzheimer's disease – are we there yet?
Fradinger, E. A., & Bitan, G. (2005) · Trends in biotechnology · doi:10.1016/j.tibtech.2005.09.002 · Cited by 22
Cehlár, O., Njemoga, S., Horvath, M., Cizmazia, E., Bednáriková, Z., & Barrera, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313049 · Cited by 23
Alzheimer’s disease is an inherent, natural part of human brain aging: an integrated perspective
Ferrer, I. (2022) · Free Neuropathology · doi:10.17879/freeneuropathology-2022-3806 · Cited by 25
Feng, L., Watanabe, H., Molino, P. J., Wallace, G. G., Phung, S. L., Uchihashi, T., & Higgins, M. J. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.04.044 · Cited by 21
Development and Expression of Amyloid‐β Peptide 42 in Retinal Ganglion Cells in Rats
Wang, J., Zhu, C., Xu, Y., Liu, B., Wang, M., & Wu, K. (2011) · The Anatomical Record · doi:10.1002/ar.21438 · Cited by 21
Fibrillar and Oligomeric β‐Amyloid as Distinct Local Biomarkers for Alzheimer's Disease
Montalto, M., Farrar, G., & Hehir, C. A. T. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1379.023 · Cited by 22
Inherent Anti-amyloidogenic Activity of Human Immunoglobulin γ Heavy Chains
Adekar, S. P., Klyubin, I. V., Macy, S., Rowan, M. J., Solomon, A., Dessain, S. K., & O’Nuallain, B. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.044321 · Cited by 21
Kelly, J. W. (2005) · New England Journal of Medicine · doi:10.1056/nejmcibr044231 · Cited by 21
Anti-oxidative and Neuroprotective Activities of Pig Skin Gelatin Hydrolysates
Kim, D. W., Park, K., Ha, G. E., Jung, J. R., Chang, O.-K., Ham, J.-S., Jeong, S.-G., Park, B.-Y., Song, J., & Jang, A. (2013) · Korean Journal for Food Science of Animal Resources · doi:10.5851/kosfa.2013.33.2.258 · Cited by 20
Republished: The role of amyloid β in the pathogenesis of Alzheimer’s disease
Gilbert, B. J. (2014) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2013-201515rep · Cited by 20
Wu, G., & Hou, X. (2010) · Brain Research · doi:10.1016/j.brainres.2010.04.055 · Cited by 20
Williams, T. L., Choi, J.-K., Surewicz, K. A., & Surewicz, W. K. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00229 · Cited by 20
Lindner, M. D., McArthur, R. A., Deadwyler, S. A., Hampson, R. E., & Tariot, P. N. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00016-3 · Cited by 20
Kitazawa, M., Vasilevko, V., Cribbs, D. H., & LaFerla, F. M. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1150-09.2009 · Cited by 20
Santos, A. N., Simm, A., Holthoff‐Detto, V., & Boehm, G. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14201 · Cited by 20
Sun, P., Ding, H., Liang, M., Li, X., Mo, W., Wang, X., Liu, Y. M., He, R., & Hua, Q. (2014) · BioMed Research International · doi:10.1155/2014/284314 · Cited by 20
Nazem, A. (2014) · Journal of Bioanalysis & Biomedicine · doi:10.4172/1948-593x.1000101 · Cited by 20
Kaur, P., Khan, H., Grewal, A. K., Dua, K., Singh, S. K., Gupta, G., & Singh, T. G. (2024) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273321002240919102841 · Cited by 19
Amyloid PET detects the deposition of brain Aβ earlier than CSF fluid biomarkers
Lowe, V. J., Mester, C. T., Lundt, E. S., Lee, J., Ghatamaneni, S., Algeciras‐Schimnich, A., Campbell, M. R., Graff‐Radford, J., Nguyen, A. T., Min, H.-K. P., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14317 · Cited by 20
Rajadas, J., Liu, C. W., Novick, P. A., Kelley, N. W., Inayathullah, M., LeMieux, M. C., & Pande, V. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021776 · Cited by 19
Soluble state high resolution atomic force microscopy study of Alzheimer’s β-amyloid oligomers
Shekhawat, G. S., Lambert, M. P., Sharma, S., Velasco, P. T., Viola, K. L., Klein, W. L., & Dravid, V. P. (2009) · Applied Physics Letters · doi:10.1063/1.3251779 · Cited by 19
Self-citationDhouafli, Z., Rigacci, S., Leri, M., Bucciantini, M., Mahjoub, B., Tounsi, M. S., Wannes, W. A., Stefani, M., & Hayouni, E. A. (2017) · Industrial Crops and Products · doi:10.1016/j.indcrop.2017.11.045 · Cited by 19
Identification of prion protein-derived peptides of potential use in Alzheimer's disease therapy
Nieznańska, H., Bandyszewska, M., Surewicz, K. A., Zajkowski, T., Surewicz, W. K., & Nieznański, K. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.03.023 · Cited by 19
Early mechanisms of amyloid fibril nucleation in model and disease-related proteins
Morel, B., & Conejero‐Lara, F. (2019) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2019.140264 · Cited by 19
Regulation of microRNAs in Alzheimer´s disease, type 2 diabetes, and aerobic exercise training
Sousa, R. A. L. D., & Caria, A. C. I. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-00903-y · Cited by 19
Romanelli, M. N., Galeotti, N., Ghelardini, C., Manetti, D., Martini, E., & Gualtieri, F. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00039.x · Cited by 19
Stability of early-stage amyloid-β(1–42) aggregation species
Coalier, K. A., Paranjape, G. S., Karki, S., & Nichols, M. R. (2012) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2012.08.017 · Cited by 20
Metadata
- Authors
- Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L.
- Affiliations
- Northwestern University (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2003-08-18
- Volume
- 100
- Issue
- 18
- Pages
- 10417-10422
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC193576
- OpenAlex
- W2040721710
- Cited by
- 1,061
- References
- 55
- Citations by year
- 2026: 21 · 2025: 15 · 2024: 19 · 2023: 32 · 2022: 24 · 2021: 33 · 2020: 35 · 2019: 38 · 2018: 44 · 2017: 45 · 2016: 32 · 2015: 42 · 2014: 52 · 2013: 49 · 2012: 53
- FWCI
- 35.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Northwestern University
- National Institutes of Health (1p01ag015501-01)
- National Institute on Aging (P01-AG15501, R01-AG18877, R01AG018877)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta oligomers, memory loss, hippocampal long-term potentiation, synaptic plasticity, synaptic loss, frontal cortex, dendrites, protein-ligand binding, amyloid plaques, therapeutic vaccines
- MeSH terms
- Alzheimer Disease, Animals, Binding Sites, Brain Chemistry, Cells, Cultured, Cerebral Cortex, Ligands, Neurons, Oligopeptides, Peptide Fragments, Tissue Extracts, Immunoblotting, Amyloid beta-Peptides, Rats, Sprague-Dawley, Long-Term Potentiation, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
